GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-07-13| Technology

Abbott’s Looks to Treat Depression With Breakthrough Device Status

by Joy Lin
Share To

Abbott has announced that its deep brain stimulation (DBS) system has been granted US FDA Breakthrough Device Designation for treatment-resistant depression (TRD), a form of major depressive disorder. Breakthrough Device status helps speed up the regulatory review process, possibly giving patients earlier access to Abbott’s DBS system. 

“Breakthrough product development always requires bold thinking and collaboration, and Abbott is fully committed to the journey of providing people with new therapeutic options for their treatment-resistant depression,” said Pedro Malha, Vice President of Neuromodulation at Abbott.

Related article: Alleviating Depression and Dementia with Transcorneal Electrical Stimulation

 

A Neurosurgical Solution to Depression

 

Each year, 2.8 million Americans will fail multiple depression treatments and be diagnosed with TRD. The condition is thought to cost the US an estimated $44 billion a year in healthcare, unemployment, and lost productivity. 

DBS is under investigation as a possible treatment for TRD when antidepressants and other device therapies fail. Abbott’s system is designed to be adjusted to the individual’s needs, and involves implanting thin wires called leads into target areas in the brain. The leads are connected to a pulse generator implanted under the skin in the chest, which will produce electrical impulses to modulate abnormal brain activity. 

Abbott’s DBS system has been used in Parkinson’s disease, in which implanted leads regulate abnormal neurons that cause tremor. For TRD, the company has found that implanting electrodes in the part of the brain that regulates mood may reduce disease symptoms. Abbott is now working with the FDA to evaluate the device’s safety and effectiveness for TRD. 

An additional benefit of the system is the ability to be used with Neurosphere Virtual Clinic, a remote platform that allows patients to communicate and receive care from their doctors, all from the comforts of home.

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
Easing the Mental Health Burden: How MDMA, Psilocybin, and Other Psychedelics May Open Doors for Treating PTSD, Addiction, and Autism
2025-01-28
Drug Promotion, Nonprescription Pathways, and Advanced Manufacturing: FDA’s Key Focus Areas in 2024 and What’s Next for 2025
2025-01-23
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top